- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- DI-Leu16-IL2 immunocytokine, rituximab, flow cytometry, immunohistochemistry staining method, pharmacological study, laboratory biomarker analysis, enzyme-linked immunosorbent assay, reverse transcriptase-polymerase chain reaction
- Biological · Other · Genetic
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Duarte, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Melanoma
- Interventions
- Poly ICLC, leukapheresis
- Drug · Procedure
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Multiple Myeloma
- Interventions
- Activated marrow infiltrating lymphocytes, Allogeneic Myeloma Vaccine, Cyclophosphamide, Filgrastim, Leukapheresis, Melphalan, Autologous stem cell transplant
- Biological · Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2020
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Head and Neck Cancer
- Interventions
- EF5, bioluminescence, flow cytometry, immunohistochemistry staining method, biopsy
- Drug · Other · Procedure
- Lead sponsor
- David M. Brizel, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Fludarabine, Cyclophosphamide, Leukapheresis, Cytokine-induced killer cells, IL-2, ALT-803, Peripheral blood for correlative studies, Bone marrow for correlative studies
- Drug · Procedure · Biological
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2022
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Crohn Disease
- Interventions
- Mesna, Cyclophosphamide, Filgrastim, Apheresis catheter placement, Leukapheresis, Fludarabine, Methylprednisolone, Diphenhydramine, Acetaminophen, anti-thymocyte globulin (rabbit), lymphocyte immune globulin, Peripheral Blood Stem Cell Infusion, Cytoxan
- Drug · Procedure · Biological
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 13 Years to 28 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Primary Mediastinal Large B-Cell Lymphoma
- Interventions
- Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, Leukapheresis, Lisocabtagene Maraleucel, Lumbar Puncture, Lymphodepletion Therapy, Multigated Acquisition Scan, Positron Emission Tomography, X-Ray Imaging, Biospecimen Collection
- Biological · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Refractory Multiple Myeloma
- Interventions
- azacitidine, lenalidomide, dexamethasone, DNA methylation analysis, gene expression analysis, bone marrow aspiration, immunohistochemistry staining method, reverse transcriptase-polymerase chain reaction, flow cytometry
- Drug · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Diamond Blackfan Anemia
- Interventions
- G-CSF, Leukapheresis
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Multiple Myeloma
- Interventions
- Pegfilgrastim (Neulasta), Apheresis
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- Questionnaire, Interactive Voice Response Telephone System, IVR Plus Triage
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive, Recurrent Ovarian Carcinoma
- Interventions
- Aldesleukin, CD8-Positive T-Lymphocyte, Cyclophosphamide, Leukapheresis, Utomilumab
- Biological · Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Breast Cancer
- Interventions
- HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement
- Biological · Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Seattle, Washington
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
- Interventions
- Anti-GPC3-CAR Autologous T Lymphocytes, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography Test, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Multigated Acquisition Scan
- Biological · Procedure · Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Leukemia
- Interventions
- dasatinib, vorinostat, cytogenetic analysis, gene expression analysis, mutation analysis, reverse transcriptase-polymerase chain reaction, flow cytometry, laboratory biomarker analysis
- Drug · Genetic · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 2
- States / cities
- Duarte, California • Pasadena, California
- Conditions
- Childhood Cancer
- Interventions
- Not listed
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Sickle Cell Trait
- Interventions
- Granulocyte colony-stimulating factor, Leukapheresis
- Drug · Procedure
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- Not listed
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer
- Interventions
- PEG-interferon alfa-2b, Sorafenib, gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, flow cytometry, immunoenzyme technique, laboratory biomarker analysis
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- Thomas Olencki
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Hematopoietic Stem Cell Transplantation
- Interventions
- CD3+ T cell depletion
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2026
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Computed Tomography, Leukapheresis, Lutetium Lu 177 Vipivotide Tetraxetan, Magnetic Resonance Imaging, PSMA PET Scan, Sipuleucel-T
- Procedure · Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Breast Cancer
- Interventions
- therapeutic autologous lymphocytes, Ifosfamide, carboplatin, and etoposide (ICE) regimen, Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC), Leukapheresis, peripheral blood stem cell transplantation (PBSCT)
- Biological · Drug · Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma, IDH-Wildtype
- Interventions
- Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells, Biopsy Procedure, Biospecimen Collection, Echocardiography Test, FDG-Positron Emission Tomography, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Resection
- Biological · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Aldesleukin, Anti-HLA-A2/NY-ESO-1 TCR-transduced Autologous T Lymphocytes, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Leukapheresis, Magnetic Resonance Imaging, Mammogram, Multigated Acquisition Scan, Ultrasound Imaging
- Biological · Procedure · Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- fluorouracil, irinotecan hydrochloride, leucovorin calcium, sunitinib malate, flow cytometry, pharmacological study
- Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- Up to 120 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York